-
1.发明公开
公开(公告)号：EP4435094A1
公开(公告)日：2024-09-25
申请号：EP22895627.2
申请日：2022-11-16
发明人： IWATA Takanori , ONIZUKA Satoru
IPC分类号： C12N5/0775
CPC分类号： C12N5/06
摘要： The present invention is directed to obtaining a cell population comprising mesenchymal stem cells that are excellent in proliferative capability and osteoblastic differentiation capability and are useful for the regeneration of periodontal tissues. The present invention is also directed to providing a cell sheet and a method for producing a cell sheet, comprising, as a material, a cell population comprising mesenchymal stem cells that are excellent in proliferative capability and osteoblastic differentiation capability and are useful for the regeneration of periodontal tissues. A cell population having alkaline phosphatase activity before calcification induction of 1 U or more is selected and obtained from a cell population comprising mesenchymal stem cells derived from a dental or periodontal tissue. A cell sheet is obtained by the following steps (a) to (c): (a) obtaining a cell population comprising mesenchymal stem cells and having alkaline phosphatase activity; (b) culturing the cell population in a calcification induction medium, and proliferating the cell population on a plastic substrate; and (c) recovering and washing a sheet-shaped cell population formed on the plastic substrate.
-
公开(公告)号：EP4372077A1
公开(公告)日：2024-05-22
申请号：EP22842098.0
申请日：2022-07-12
CPC分类号： A61K35/747 , A61P1/00 , A61P43/00 , C12N1/20 , C12R2001/02520210501 , C12R2001/2320210501 , C12R2001/24520210501
摘要： A composition comprising an ingredient that is effective for inducing autophagy in intestinal epithelial cells and intestinal epithelial stem cells and can be ingested at ease on a daily basis is provided. A composition for inducing autophagy, the composition comprising bacterial cells of a lactic acid bacterium belonging to the family Lactobacillaceae is provided. The lactic acid bacterium is preferably a lactic acid bacterium belonging to any of the genera Lactiplantibacillus, Lactobacillus, Lacticaseibacillus, Companilactobacillus, and Limosilactobacillus.
-
公开(公告)号：EP4293113A3
公开(公告)日：2024-04-10
申请号：EP23186406.7
申请日：2017-05-10
申请人： National University Corporation Tokyo Medical and Dental University , Nippon Zoki Pharmaceutical Co., Ltd.
发明人： ASAHARA, Hiroshi , CHIBA, Tomoki , ABE, Kentaro
摘要： Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for said method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.
-
公开(公告)号：EP4321165A2
公开(公告)日：2024-02-14
申请号：EP23215585.3
申请日：2014-12-25
发明人： OKAZAWA, Hitoshi
IPC分类号： A61K31/506
摘要： It has been revealed that, from a pre-onset stage of Alzheimer's disease, enhancement of phosphorylations of MARCKS and the like causes abnormal spine formation or the like, consequently developing the disease. Moreover, it has also been revealed that the phosphorylations of MARCKS and the like are caused by PKC and the like, and further that b-raf is involved in the phosphorylation of a tau protein important for the progression of Alzheimer's disease. Thus, these proteins have been found to be target molecules useful in the diagnosis and treatment of Alzheimer's disease. In addition, it has also been revealed that, in a pre-onset stage of frontotemporal lobar degeneration also, b-RAF phosphorylation enhancement causes a decrease in the number of spines and the like, consequently developing the disease. Thus, b-RAF has been found to be a target molecule useful in the diagnosis and treatment of frontotemporal lobar degeneration.
-
公开(公告)号：EP4293113A2
公开(公告)日：2023-12-20
申请号：EP23186406.7
申请日：2017-05-10
申请人： National University Corporation Tokyo Medical and Dental University , Nippon Zoki Pharmaceutical Co., Ltd.
发明人： ASAHARA, Hiroshi , CHIBA, Tomoki , ABE, Kentaro
IPC分类号： C12N15/09
摘要： Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for said method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.
-
6.发明公开
公开(公告)号：EP4277528A1
公开(公告)日：2023-11-22
申请号：EP22701730.8
申请日：2022-01-11
-
公开(公告)号：EP4145130A1
公开(公告)日：2023-03-08
申请号：EP21797405.4
申请日：2021-04-22
发明人： MIYAHARA Yuji , TABATA Miyuki
IPC分类号： G01N33/53 , G01N33/543
摘要： An object of the present invention is to provide a method, a device, and a system for detecting or measuring a biological vesicle having a size of 20 microns or smaller, such as a cell, an exosome, or an extracellular vesicle among target substances detected by liquid biopsy, in a body fluid-derived sample and quantitatively analyzing the expression level of a target marker molecule, such as a protein, present on the surface thereof. It was demonstrated that a method for qualitatively or quantitatively analyzing the expression of a plurality of target marker molecules and a device and a system therefor could be provided by capturing a body fluid-derived sample containing a plurality of target marker molecules on a support and detecting or measuring the plurality of target marker molecules using an identification substance, such as an antibody. [Selected Drawing] None
-
公开(公告)号：EP4064991A1
公开(公告)日：2022-10-05
申请号：EP20824696.7
申请日：2020-11-25
IPC分类号： A61B5/243 , A61B6/00 , A61B5/0522 , A61B5/242
-
公开(公告)号：EP4043565A1
公开(公告)日：2022-08-17
申请号：EP20875085.1
申请日：2020-10-09
申请人： National University Corporation Tokyo Medical and Dental University , Takeda Pharmaceutical Company Limited
发明人： YOKOTA Takanori , NAGATA Tetsuya , YAMADA Hiroki , FURUKAWA Hideki , YOGO Takatoshi , MIYATA Kenichi , UCHIDA Akio , TOMITA Naoki
IPC分类号： C12N15/113 , A61K31/713
摘要： In an embodiment, an object of the present invention is to provide a double-stranded nucleic acid complex having a novel structure.
In an embodiment, the present invention relates to a nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein said first nucleic acid strand: (1) is capable of hybridizing to at least a part of a target transcriptional product; (2) has an antisense effect on the target transcriptional product; and (3) is a gapmer comprising a central region, and a 5' wing region and a 3' wing region, said second nucleic acid strand comprises at least one sugar-unmodified central region (first exposed region) consisting of one sugar-unmodified ribonucleoside or two or three contiguous sugar-unmodified ribonucleosides linked by an internucleoside bond, which is or are complementary to a part of said first nucleic acid strand, and said first nucleic acid strand is annealed to said second nucleic acid strand.-
公开(公告)号：EP3978020A1
公开(公告)日：2022-04-06
申请号：EP20778483.6
申请日：2020-03-26
发明人： NISHIMURA Emi
IPC分类号： A61K45/06
摘要： The present invention pertains to: the provision of a method for promoting skin wound healing and a composition to be used for promoting skin wound healing; the provision of a method useful for preventing or ameliorating ulcers and bedsores or a composition therefor; the provision of a method for preventing skin aging and a composition to be used for preventing skin aging; the provision of a composition useful for preventing or ameliorating skin damage caused by an anticancer agent; and, furthermore, the provision of a method for enhancing the regeneration ability of epidermal stem cells and a composition for enhancing the regeneration ability of epidermal stem cells. More specifically, use of a composition, said composition being characterized by comprising, as an active ingredient, a substance selected from the group consisting of a substance which induces or maintains the expression of COL17A1 in cells, a substance which inhibits the degradation of COL17A1 in cells, a substance which promotes the competitive amplification ability of epidermal stem cells, a substance which suppresses genomic stress or oxidative stress in cells and a substance which prevents DNA damage in cells, enables the promotion of skin wound healing, protection from an anticancer agent and prevention of skin aging. Thus, the regeneration ability of epidermal stem cells can be enhanced.
-
-
-
-
-
-
-
-
-
搜索结果
248 条记录 (耗时 0.027 秒)
